BR0307406A - Indóis substituìdos como agonistas alfa-1 - Google Patents

Indóis substituìdos como agonistas alfa-1

Info

Publication number
BR0307406A
BR0307406A BR0307406-4A BR0307406A BR0307406A BR 0307406 A BR0307406 A BR 0307406A BR 0307406 A BR0307406 A BR 0307406A BR 0307406 A BR0307406 A BR 0307406A
Authority
BR
Brazil
Prior art keywords
alpha
agonists
indols
replaced
alkyl
Prior art date
Application number
BR0307406-4A
Other languages
English (en)
Inventor
Robert Greenhouse
Saul Jaime-Figueroa
Lubica Raptova
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR0307406A publication Critical patent/BR0307406A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Abstract

"INDóIS SUBSTITUìDOS COMO AGONISTAS ALFA-1". Esta invenção diz respeito a compostos que são agonistas receptores alfa-1, preferivelmente agonistas receptores alfa-1A/L, e que são representados pela fórmula geral I em que X é -S(O)~ n~- ou -C(O)-, A é alquila (C~ 1-6~), arila, heteroarila, hidróxi-alquila (C~ 1-6~), ou -(CH~ 2~)~ P~-NR^ a^R^ b^, e os outros substituintes são como definidos no relatório descritivo; ou isómeros individuais, ou misturas racêmicas ou não racêmicas de isómeros, ou sais ou solvatos farmaceuticamente aceitáveis destes. A invenção ainda diz respeito às composições farmacêuticas contendo tais compostos, sua preparação e seu uso como agentes terapêuticos.
BR0307406-4A 2002-02-01 2003-01-23 Indóis substituìdos como agonistas alfa-1 BR0307406A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35350802P 2002-02-01 2002-02-01
US41849202P 2002-10-15 2002-10-15
PCT/EP2003/000644 WO2003064387A2 (en) 2002-02-01 2003-01-23 Substituted indoles as alpha-1 agonists

Publications (1)

Publication Number Publication Date
BR0307406A true BR0307406A (pt) 2004-12-28

Family

ID=27669110

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0307406-4A BR0307406A (pt) 2002-02-01 2003-01-23 Indóis substituìdos como agonistas alfa-1

Country Status (18)

Country Link
US (1) US6852726B2 (pt)
EP (1) EP1501826B1 (pt)
JP (1) JP4209332B2 (pt)
KR (1) KR100656037B1 (pt)
CN (1) CN100378095C (pt)
AR (1) AR038341A1 (pt)
AT (1) ATE340792T1 (pt)
AU (1) AU2003218962B2 (pt)
BR (1) BR0307406A (pt)
CA (1) CA2473803A1 (pt)
DE (1) DE60308670T2 (pt)
DK (1) DK1501826T3 (pt)
ES (1) ES2271551T3 (pt)
MX (1) MXPA04007414A (pt)
PL (1) PL373410A1 (pt)
PT (1) PT1501826E (pt)
RU (1) RU2337909C2 (pt)
WO (1) WO2003064387A2 (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
TW200307542A (en) 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
KR20050072812A (ko) 2002-11-07 2005-07-12 악조 노벨 엔.브이. 안드로겐-수용체와 관련된 질병의 치료에 효과적인 인돌
UA79504C2 (en) * 2002-11-07 2007-06-25 Organon Nv Indols for treating diseases associated with androgen receptors
SE0301010D0 (sv) 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
RU2313524C2 (ru) * 2003-05-09 2007-12-27 Ф.Хоффманн-Ля Рош Аг МИТИЛИНДОЛЫ И МЕТИЛПИРРОЛОПИРИДИНЫ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ОБЛАДАЮЩАЯ АКТИВНОСТЬЮ α-1-АДРЕНЕРГИЧЕСКИХ АГОНИСТОВ
SE0301569D0 (sv) 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
SE0302232D0 (sv) * 2003-08-18 2003-08-18 Astrazeneca Ab Novel Compounds
SA04250253B1 (ar) 2003-08-21 2009-11-10 استرازينيكا ايه بي احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
EP1675826A1 (en) * 2003-10-14 2006-07-05 Oxagen Limited Compounds having crth2 antagonist activity
JP4448730B2 (ja) * 2004-04-20 2010-04-14 富士フイルム株式会社 感光性組成物、該感光性組成物に用いられる化合物及び該感光性組成物を用いたパターン形成方法
TW200602317A (en) * 2004-04-23 2006-01-16 Akzo Nobel Nv Novel androgens
GB0415320D0 (en) 2004-07-08 2004-08-11 Astrazeneca Ab Novel compounds
GB0418830D0 (en) 2004-08-24 2004-09-22 Astrazeneca Ab Novel compounds
SI1817282T1 (sl) 2004-11-23 2011-10-28 Astrazeneca Ab Derivati fenoksiocetne kisline, uporabni za zdravljenje respiratornih bolezni
AU2005311826A1 (en) * 2004-11-30 2006-06-08 Plexxikon, Inc. Indole derivatives for use as PPAR active compounds
JP2008521829A (ja) 2004-11-30 2008-06-26 プレキシコン，インコーポレーテッド Ｐｐａｒ活性化合物
GB0500604D0 (en) 2005-01-13 2005-02-16 Astrazeneca Ab Novel process
CA2637141C (en) * 2005-01-14 2015-06-09 Urigen Pharmaceuticals, Inc. Kits and improved compositions for treating lower urinary tract disorders
CN101283077B (zh) * 2005-08-22 2012-05-02 国际壳牌研究有限公司 柴油和操作柴油发动机的方法
TW200745003A (en) 2005-10-06 2007-12-16 Astrazeneca Ab Novel compounds
US8148572B2 (en) 2005-10-06 2012-04-03 Astrazeneca Ab Compounds
AU2007214434B2 (en) * 2006-02-15 2012-06-14 Allergan, Inc. Indole-3-carboxylic acid amide, ester, thioamide and thiol ester compounds bearing aryl or heteroaryl groups having sphingosine-1-phosphate (S1P) receptor antagonist biological activity
CN101460458A (zh) * 2006-02-15 2009-06-17 阿勒根公司 具有1－磷酸－鞘氨醇(s1p)受体拮抗剂生物活性的带芳基或者杂芳基基团的吲哚－3－羧酸的酰胺、酯、硫代酰胺和硫羟酸酯化合物
CN102558021A (zh) 2006-05-26 2012-07-11 阿斯利康(瑞典)有限公司 联芳基或芳基-杂芳基取代的吲哚类化合物
PE20090159A1 (es) 2007-03-08 2009-02-21 Plexxikon Inc COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs
UA100983C2 (ru) 2007-07-05 2013-02-25 Астразенека Аб Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты
EA022476B1 (ru) * 2008-05-05 2016-01-29 Лонца Лтд. Индолсульфонильные защищенные соединения и способ их получения
EP2246326A1 (de) * 2009-05-02 2010-11-03 Bayer CropScience AG Verfahren zur Herstellung von Oxindolen und ortho-substituierten Anilinen und ihre Verwendung als Zwischenprodukte für Synthesen
CA2797281A1 (en) * 2010-05-06 2011-11-10 Merck Sharp & Dohme Corp. Aza-indole derivatives useful as modulators of faah
TWI695831B (zh) * 2014-09-13 2020-06-11 香港商南北兄弟藥業投資有限公司 Ｃｒｔｈ２拮抗劑化合物及其用途
CN106674081A (zh) * 2016-12-18 2017-05-17 南京理工大学 一种3‑甲硫基吲哚衍生物合成方法
WO2020180876A1 (en) * 2019-03-04 2020-09-10 Beth Israel Deaconess Medical Center, Inc. Orai channel inhibitors
CN114835677A (zh) * 2021-02-02 2022-08-02 广东东阳光药业有限公司 吲哚衍生物的盐及其用途
WO2023183394A1 (en) * 2022-03-24 2023-09-28 Curasen Therapeutics, Inc. Alpha 1a-adrenergic receptor agonists and methods of use

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3404156A (en) * 1966-02-23 1968-10-01 Sterling Drug Inc Imidazolin-2-yl-alkyl-substituted indoles
US3689655A (en) * 1970-12-07 1972-09-05 Sterling Drug Inc Rodenticidal and rodent repellent compositions
US4654360A (en) * 1984-06-01 1987-03-31 Syntex (U.S.A.) Inc. 1,2,3-trisubstituted indoles for treatment of inflammation
US5095031A (en) 1990-08-20 1992-03-10 Abbott Laboratories Indole derivatives which inhibit leukotriene biosynthesis
US5334597A (en) 1991-10-17 1994-08-02 Merck Frosst Canada, Inc. Indole carbamates as leukotriene antagonists
ZA939516B (en) 1992-12-22 1994-06-06 Smithkline Beecham Corp Endothelin receptor antagonists
US6175013B1 (en) * 1994-06-10 2001-01-16 Eli Lilly And Company Imidazolinyl tachykinin receptor antagonists
DE19514579A1 (de) * 1995-04-20 1996-10-24 Boehringer Ingelheim Kg Verwendung von alpha¶1¶¶L¶-Agonisten zur Behandlung der Harninkontinenz
FR2735774B1 (fr) 1995-06-21 1997-09-12 Sanofi Sa Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant
CA2203912A1 (en) 1995-09-01 1997-03-13 Dennis Michael Zimmerman Indolyl neuropeptide y receptor antagonists
SG72827A1 (en) * 1997-06-23 2000-05-23 Hoffmann La Roche Phenyl-and aminophenyl-alkylsulfonamide and urea derivatives
ATE239013T1 (de) 1997-12-19 2003-05-15 Lilly Co Eli Hypoglykamische imidazoline derivate
GB9910110D0 (en) * 1999-04-30 1999-06-30 Glaxo Group Ltd Chemical compounds
US6323231B1 (en) * 2000-02-17 2001-11-27 Abbott Laboratories Use of α1A adrenoceptor agonists with α1B and α1D antagonism for the treatment of stress urinary incontinence

Also Published As

Publication number Publication date
EP1501826B1 (en) 2006-09-27
US20030220319A1 (en) 2003-11-27
ATE340792T1 (de) 2006-10-15
WO2003064387A2 (en) 2003-08-07
AU2003218962B2 (en) 2008-09-25
EP1501826A2 (en) 2005-02-02
WO2003064387A3 (en) 2004-12-02
AR038341A1 (es) 2005-01-12
DE60308670T2 (de) 2007-08-16
RU2004126613A (ru) 2005-07-10
DK1501826T3 (da) 2007-01-29
MXPA04007414A (es) 2004-10-11
PT1501826E (pt) 2007-01-31
PL373410A1 (en) 2005-08-22
ES2271551T3 (es) 2007-04-16
KR100656037B1 (ko) 2006-12-11
CN100378095C (zh) 2008-04-02
DE60308670D1 (de) 2006-11-09
KR20040077927A (ko) 2004-09-07
CA2473803A1 (en) 2003-08-07
US6852726B2 (en) 2005-02-08
CN1628113A (zh) 2005-06-15
JP2005522427A (ja) 2005-07-28
RU2337909C2 (ru) 2008-11-10
JP4209332B2 (ja) 2009-01-14

Similar Documents

Publication Publication Date Title
BR0307406A (pt) Indóis substituìdos como agonistas alfa-1
BR9913542A (pt) Derivados de dihidrobenzodioxina carboxamida e dihidrobenzodioxina cetona como antagonistas do receptor 5-ht4
BR0315317A (pt) 4-piperazinil benzenossulfonil indóis com afinidade para o receptor de 5-ht6
BR0307409A (pt) Compostos de hidrazida de ácido 2-furanocarboxìlico, composições farmacêuticas contendo os mesmos e uso dos mesmos para preparação de um agente preventivo ou terapêutico
BR0210411A (pt) Derivados 4-piperazinilindol com afinidade para o receptor 5-ht6
BR0210929A (pt) Derivados de indol com afinidade para o receptor 5-ht6
BRPI0409986A (pt) derivados de pirimidina fundida com atividade de crf
BR0316950A (pt) Derivados de indazol como antagonistas de crf
BR0109235A (pt) Derivados do ácido carboxìlico como antagonistas ip
BR0116662A (pt) Derivados de quinazolona como antagonistas receptores alfa 1a/b adrenérgicos
NO20025641D0 (no) Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister
BR9810544A (pt) Derivados de azetidinilpropilpiperidina, intermediários e uso como antagonistas de taquicinina
NO20025640D0 (no) Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister
NO20040589L (no) Arylsulfonylderivater med 5-HT6 reseptor affinitet.
BR0214674A (pt) Derivados 4-piperdinil alquilamina como antagonistas do receptor muscarìnico
BR0214695A (pt) Derivados de pirazol com anel fundido
BR0207795A (pt) Derivados de ácido alcoxicarbonilamino benzóico ou alcoxicarbonilamino tetrazolil fenila como antagonistas de ip
BR0214649A (pt) Derivados de aminotetralina como antagonistas do receptor muscarìnico
BR9905974A (pt) Derivados de ácido aril carboxìlico e tetrazol
BR0207730A (pt) Derivados de ácido alcoxicarbonila-mino-heteroaril carboxìlico, como antagonistas de ip
BRPI0410237A (pt) metil indóis e metil pirrolopiridinas como agonistas adrenérgicos alfa-1
EA200600022A1 (ru) Применение производных бицикло [2.2.1] гептана для приготовления нейропротекторных фармацевтических композиций
BRPI0415546A (pt) composto, composição farmacêutica, uso de um composto, e, métodos de tratamento ou profilaxia de doenças ou condições humanas, e de distúrbios
ECSP993127A (es) Derivados de dihidrobenzodioxina carboxamida y cetona
EA200500235A1 (ru) Новые производные пиперазинона для лечения нарушений, связанных с 5-ht-рецептором

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. A61K 31/4178, 31/506, 31/5377; A61P 1/14, 11/02, 13/00, 15/10, 25/22, 25/24, 25/28, 27/16, 29/00, 43/00, 7/12; C07D 209/00, 403/06, 495/04

Ipc: A61K 31/4178 (2011.01), A61K 31/506 (2011.01), A61

B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 10A E 11A ANUIDADES.

B08I Publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2258 DE 15/04/2014 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 10A, 11A, 12A, 13A, 14A, 15A, 16A E 17A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.